Sita Yanamadala, MD
Nephrology · Lynwood, CANPI 1821049255
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Amgen at 45.6% of the total. That places this record below the midpoint for nephrology clinicians in CA, where the typical reported total is $1,018.
Across 7 payments — averaging $27.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$89
- Ardelyx, Inc.$27
- GSK$26
- Fresenius USA Marketing, Inc.$24
- Akebia Therapeutics Inc$15
- Calliditas Therapeutics US Inc.$14
Across 174 payments — averaging $2549.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$403K
- Gilead$15K
- Eli Lilly$13K
- Alnylam Pharmaceuticals Inc.$8K
- Novo Nordisk AS$5K
What the payments were for
- Food & beverage$18193%
- Education$147%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 2 | $89 |
| Ardelyx, Inc. | 1 | $27 |
| GSK | 1 | $26 |
| Fresenius USA Marketing, Inc. | 1 | $24 |
| Akebia Therapeutics Inc | 1 | $15 |
| Calliditas Therapeutics US Inc. | 1 | $14 |
How this compares
$195 in reported general payments places this provider in the 20th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 298 | $184,746 |
| Sevelamer Hcl | 27 | $55,229 |
| ProcritEpoetin Alfa | 47 | $44,733 |
| DapagliflozinDapagliflozin Propanediol | 71 | $38,452 |
| KerendiaFinerenone | 13 | $17,189 |
| Sevelamer Carbonate | 70 | $13,413 |
| RayaldeeCalcifediol | 11 | $12,528 |
| ProsolParenteral Amino Acid 20% No.1 | 66 | $10,594 |
| Calcium Acetate | 42 | $4,917 |
| Midodrine Hcl | 15 | $815 |
| Furosemide | 70 | $804 |
| Gentamicin Sulfate | 18 | $774 |
| Potassium Chloride | 48 | $598 |
| Hydralazine Hcl | 42 | $318 |
| Allopurinol | 42 | $261 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Lynwood
- Brian LeeLynwood$77K
- Anjay RastogiLos Angeles$2.2M
- Glenn ChertowStanford$2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.